Skip to product information
1 of 3

CFB Rabbit Polyclonal Antibody

CFB Rabbit Polyclonal Antibody

Catalog Number: S0B60813 Application: WB Reactivity: Hu, Ms, Rt Conjugation: Unconjugated Brand: Starter
Price:
Regular price $100 USD
Regular price Sale price $100 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Rabbit
Antigen CFB
Synonyms Complement factor B; C3/C5 convertase; Glycine-rich beta glycoprotein (GBG); PBF2; Properdin factor B; BF; BFD
Immunogen Recombinant Protein
Location Secreted
Accession P00751
Antibody Type Polyclonal antibody
Isotype IgG
Application WB
Reactivity Hu, Ms, Rt
Positive Sample Human serum, Human plasma, mouse plasma, rat plasma
Predicted Reactivity Or, Cz, Gor
Purification Protein A
Concentration 0.5 mg/ml
Conjugation Unconjugated
Physical Appearance Liquid
Storage Buffer

PBS, 40% Glycerol, 0.05% BSA, 0.02% sodium azide

Stability & Storage

12 months from date of receipt / reconstitution, -20 °C as supplied

Dilution


application dilution species
WB 1:1000 Hu, Ms, Rt

Background

Complement factor B (CFB) is the core serine protease of the alternative complement pathway, encoded by the CFB gene located in the MHC class III region on human chromosome 6, and secreted into plasma as a single-chain zymogen of approximately 90 kDa. Its structure comprises three modules: three N-terminal complement control protein domains, a central von Willebrand factor A (VWA) domain, and a C-terminal serine protease domain; in the zymogen state, the classical activation helix of the VWA domain is replaced by a helix from the preceding linker region, safely locking the cleavage site in an inactive conformation. When the alternative pathway is initiated, CFB binds to C3b deposited on pathogen surfaces, triggering displacement of the N-terminal control domains and rearrangement of the central double helix, which exposes the site cleaved by factor D; cleavage releases the Ba fragment, and the remaining Bb fragment together with C3b forms the alternative pathway C3 convertase (C3bBb), thereby amplifying the complement cascade. At the pathological level, gain-of-function mutations in CFB can increase the stability of the C3 convertase or confer resistance to regulation by factor H, representing one of the pathogenic mechanisms of complement-mediated hemolytic uremic syndrome (CM-HUS); whereas biallelic loss-of-function mutations cause CFB deficiency, manifesting as recurrent susceptibility to encapsulated bacteria (such as Streptococcus pneumoniae and Neisseria meningitidis). Given the pivotal position of CFB in the amplification loop of the alternative pathway, its small-molecule inhibitors (such as iptacopan, which has entered phase III clinical trials, and subsequent drug candidates) have become an important strategic direction for the treatment of complement-mediated diseases including paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, and age-related macular degeneration.

Picture

Western Blot

WB result of CFB Rabbit Polyclonal Antibody
Primary antibody: CFB Rabbit Polyclonal Antibody at 1/1000 dilution
Lane 1: Human serum lysate 20 μg
Lane 2: Human plasma lysate 20 μg
Secondary antibody: Goat Anti-Rabbit IgG (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 86 kDa
Observed MW: 105 kDa

WB result of CFB Rabbit Polyclonal Antibody
Primary antibody: CFB Rabbit Polyclonal Antibody at 1/1000 dilution
Lane 1: mouse plasma lysate 20 μg
Secondary antibody: Goat Anti-Rabbit IgG (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 86 kDa
Observed MW: 105 kDa

WB result of CFB Rabbit Polyclonal Antibody
Primary antibody: CFB Rabbit Polyclonal Antibody at 1/1000 dilution
Lane 1: rat plasma lysate 20 μg
Secondary antibody: Goat Anti-Rabbit IgG (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 86 kDa
Observed MW: 105 kDa